March 24 (Reuters) - GUERBET SA GRBT.PA :
* 2019 ANNUAL RESULTS
* FY NET INCOME EUR 37.3 MILLION VERSUS EUR 46.8 MILLION
YEAR AGO
* FY EBITDA OF €111.5 MILLION, INCREASING YEAR OVER YEAR ON
A
LIKE-FOR-LIKE BASIS
* 2020 OUTLOOK: UNCERTAINTY RELATED TO MEASURES TAKEN TO
COMBAT
COVID-19 EPIDEMIC DESPITE A MINOR IMPACT ON GUERBET’S ACTIVITY
OBSERVED TO DATE
* 2020: CONTINUATION OF THE VALUE-CREATION STRATEGY
INITIATED BY
THE GROUP
* ON CORONAVIRUS: GUERBET HAS SO FAR SEEN ONLY A MINOR
IMPACT ON
ITS ACTIVITY
* DIVIDEND DISTRIBUTION OF €0.70 PER SHARE
* TO DATE, ALL OF GROUP’S PRODUCTION SITES AROUND THE WORLD
ARE
OPERATING NORMALLY, AND ALL DISTRIBUTION CENTRES ARE CONTINUING
TO SHIP ORDERS TO ALL CUSTOMERS WHEREVER THEY ARE
* THE BOARD OF DIRECTORS WILL PROPOSE A DIVIDEND OF €0.85
PER
SHARE TO THE SHAREHOLDERS AT THE GENERAL MEETING ON 29 MAY 2020
* TO COMMUNICATE MORE PRECISELY ON ITS 2020 OUTLOOK AT A
LATER
STAGE WHEN THE GROUP HAS MORE VISIBILITY ON DURATION AND SCALE
OF IMPLEMENTED MEASURE
* 2019 NET DEBT TOTALLED €296.5 MILLION INCLUDING IFRS 16
IMPACT
(€279.2 MILLION EXCLUDING IFRS 16 IMPACT)
* OUTLOOK: REGARDLESS OF COVID-19 SITUATION, ANTICIPATES ITS
REVENUE GROWTH TO BENEFIT FROM GOOD PERFORMANCE OF LIPIODOL,
CONSUMABLES FOR CONTRAST AGENT INJECTIONS, DIGITAL SOLUTIONS AND
AFTER-SALES SERVICES; GRADUAL ACCELERATION OF SALES OF ACCURATE
MICROCATHETERS
Source text: https://bit.ly/39jLxXk
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))